Whittier Trust Co. of Nevada Inc. trimmed its stake in Solventum Co. (NYSE:SOLV – Free Report) by 13.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,657 shares of the company’s stock after selling 1,152 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in Solventum were worth $534,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SOLV. Fifth Lane Capital LP purchased a new position in Solventum in the first quarter valued at about $826,000. Boit C F David purchased a new position in Solventum in the first quarter valued at about $152,000. Mitsubishi UFJ Trust & Banking Corp purchased a new position in Solventum in the first quarter valued at about $5,747,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Solventum in the first quarter valued at about $209,000. Finally, LRI Investments LLC purchased a new position in Solventum in the first quarter valued at about $43,000.
Solventum Stock Performance
Solventum stock opened at $72.61 on Wednesday. The firm’s 50 day simple moving average is $66.73 and its 200 day simple moving average is $61.10. The company has a quick ratio of 0.96, a current ratio of 1.31 and a debt-to-equity ratio of 2.90. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the stock. The Goldman Sachs Group boosted their target price on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research note on Monday, August 12th. Stifel Nicolaus started coverage on shares of Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. Wolfe Research started coverage on shares of Solventum in a research report on Thursday, September 26th. They issued a “peer perform” rating on the stock. Bank of America lowered their price target on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating on the stock in a research report on Tuesday, June 25th. Finally, Wells Fargo & Company lowered their price target on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $64.33.
Read Our Latest Research Report on Solventum
Solventum Company Profile
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Recommended Stories
- Five stocks we like better than Solventum
- How to buy stock: A step-by-step guide for beginners
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Industrial Products Stocks Investing
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Trading Stocks: RSI and Why it’s Useful
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.